Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation

Journal of Immunology

Volumn 185, Issue 5, 2010, Pages 2935-2941

  Fang, Yu ^a,b   Larsson, Lisa ^a   Mattsson, Johan ^a   Lycke, Nils ^a   Xiang, Zou ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(4 HYDROXY 3 NITROPHENYL)ACETYL; ADJUVANT; CHOLERA TOXIN; CHOLERA TOXIN A1 SUBUNIT DD; CPG OLIGODEOXYNUCLEOTIDE; HAPTEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; PROTEIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CTA1 DD PROTEIN, RECOMBINANT; CTA1-DD PROTEIN, RECOMBINANT; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; STEM CELL FACTOR RECEPTOR;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING SITE; BONE MARROW CELL; CELL ACTIVATION; CHICKEN; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOSTIMULATION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; MUCOSA CELL; NONHUMAN; NOSE MUCOSA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CULTURE; STAPHYLOCOCCUS AUREUS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C3H MOUSE; C57BL MOUSE; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MOUSE MUTANT; MUCOSAL IMMUNITY; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CELLS, CULTURED; CHOLERA TOXIN; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MUTAGENESIS, INSERTIONAL; PROTO-ONCOGENE PROTEINS C-KIT; RECOMBINANT FUSION PROTEINS;

EID: 78049358175     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000589     Document Type: Article

References (48)

1. Kalesnikoff, J., and S. J. Galli. 2008. New developments in mast cell biology. Nat. Immunol. 9: 1215-1223.
2. Hofmann, A. M., and S. N. Abraham. 2009. New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr. Opin. Immunol. 21: 679-686.
3. McLachlan, J. B., C. P. Shelburne, J. P. Hart, S. V. Pizzo, R. Goyal, R. Brooking- Dixon, H. F. Staats, and S. N. Abraham. 2008. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat. Med. 14: 536-541.
4. McGowen, A. L., L. P. Hale, C. P. Shelburne, S. N. Abraham, and H. F. Staats. 2009. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27: 3544-3552.
5. Guy, B. 2007. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5: 505-517.
6. McKee, A. S., M. W. Munks, and P. Marrack. 2007. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27: 687-690.
7. Ishii, K. J., and S. Akira. 2007. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27: 363-371.
8. Lycke, N. 2004. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann. N. Y. Acad. Sci. 1029: 193-208.
9. Lycke, N. 2005. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol. Lett. 97: 193-198.
10. Agren, L. C., L. Ekman, B. Löwenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158: 3936-3946.
11. Mowat, A. M., A. M. Donachie, S. Jägewall, K. Schön, B. Löwenadler, K. Dalsgaard, P. Kaastrup, and N. Lycke. 2001. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 167: 3398-3405.
12. De Filette, M., A. Ramne, A. Birkett, N. Lycke, B. Löwenadler, W. Min Jou, X. Saelens, and W. Fiers. 2006. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-551.
13. Akhiani, A. A., K. Schön, L. E. Franzén, J. Pappo, and N. Lycke. 2004. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J. Immunol. 172: 5024-5033.
14. Andersen, C. S., J. Dietrich, E. M. Agger, N. Y. Lycke, K. Lövgren, and P. Andersen. 2007. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75: 408-416.
15. Sundling, C., K. Schön, A. Mörner, M. N. Forsell, R. T. Wyatt, R. Thorstensson, G. B. Karlsson Hedestam, and N. Y. Lycke. 2008. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J. Gen. Virol. 89: 2954-2964.
16. W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 167: 835-848.
17. Peppoloni, S., P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, A. Podda, and G. Del Giudice. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2: 285-293.
18. Xiang, Z., and G. Nilsson. 2000. IgE receptor-mediated release of nerve growth factor by mast cells. Clin. Exp. Allergy 30: 1379-1386.
19. Xiang, Z., C. Möller, and G. Nilsson. 2006. Readministration of IgE is required for repeated passive cutaneous anaphylaxis in mice. Int. Arch. Allergy Immunol. 141: 168-171.
20. Katayama, S., H. Shionoya, and S. Ohtake. 1978. A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol. Immunol. 22: 89-101.
21. Eriksson, A. M., K. M. Schön, and N. Y. Lycke. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173: 3310-3319.
22. Malbec, O., and M. Daëron. 2007. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217: 206-221.
23. De Filette, M., W. Fiers, W. Martens, A. Birkett, A. Ramne, B. Löwenadler, N. Lycke, W. M. Jou, and X. Saelens. 2006. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597-6601.
24. Ovary, Z. 1958. Passive cutaneous anaphylaxis in the mouse. J. Immunol. 81: 355-357.
25. Braga, F., and I. Mota. 1976. Homologous passive cutaneous anaphylaxis (PCA) in mice and heterologous PCA induced in rats with mouse IgE. Immunology 30: 655-669.
26. Vliagoftis, H., and A. D. Befus. 2005. Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol. Rev. 206: 190-203.
27. Theoharides, T. C., D. Kempuraj, M. Tagen, P. Conti, and D. Kalogeromitros. 2007. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217: 65-78.
28. Gordon, J. R., and S. J. Galli. 1990. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 346: 274-276.
29. Gordon, J. R., and S. J. Galli. 1991. Release of both preformed and newly synthesized tumor necrosis factor a (TNF-a)/cachectin by mouse mast cells stimulated via the FcεRI: a mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J. Exp. Med. 174: 103-107.
30. Bradley, J. R. 2008. TNF-mediated inflammatory disease. J. Pathol. 214: 149-160.
31. Suto, H., S. Nakae, M. Kakurai, J. D. Sedgwick, M. Tsai, and S. J. Galli. 2006. Mast cell-associated TNF promotes dendritic cell migration. J. Immunol. 176: 4102-4112.
32. Shelburne, C. P., H. Nakano, A. L. St John, C. Chan, J. B. McLachlan, M. D. Gunn, H. F. Staats, and S. N. Abraham. 2009. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 6: 331-342.
33. Rivera, J., N. A. Fierro, A. Olivera, and R. Suzuki. 2008. New insights on mast cell activation via the high affinity receptor for IgE. Adv. Immunol. 98: 85-120.
34. Kuehn, H. S., and A. M. Gilfillan. 2007. G protein-coupled receptors and the modification of FcεRI-mediated mast cell activation. Immunol. Lett. 113: 59-69.
35. Ferry, X., S. Brehin, R. Kamel, and Y. Landry. 2002. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 23: 1507-1515.
36. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
37. Latour, S., C. Bonnerot, W. H. Fridman, and M. Daëron. 1992. Induction of tumor necrosis factor-α production by mast cells via FcγR: role of the FcγRIII γ subunit. J. Immunol. 149: 2155-2162.
38. Young, W. W., Jr., Y. Tamura, D. M. Wolock, and J. W. Fox. 1984. Staphylococcal protein A binding to the Fab fragments of mouse monoclonal antibodies. J. Immunol. 133: 3163-3166.
39. Roben, P. W., A. N. Salem, and G. J. Silverman. 1995. VH3 family antibodies bind domain D of staphylococcal protein A. J. Immunol. 154: 6437-6445.
40. Agren, L., E. Sverremark, L. Ekman, K. Schön, B. Löwenadler, C. Fernandez, and N. Lycke. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164: 6276-6286.
41. Qiao, S. W., W. I. Lencer, and R. S. Blumberg. 2007. How the controller is controlled - neonatal Fc receptor expression and immunoglobulin G homeostasis. Immunology 120: 145-147.
42. Groschwitz, K. R., and S. P. Hogan. 2009. Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124: 3-20, quiz 21-22.
43. Salib, R. J., S. Kumar, S. J. Wilson, and P. H. Howarth. 2004. Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-β, eotaxin, and stem cell factor and their receptors in allergic rhinitis. J. Allergy Clin. Immunol. 114: 799-806.
44. Zhu, F. G., and J. S. Marshall. 2001. CpG-containing oligodeoxynucleotides induce TNF-α and IL-6 production but not degranulation from murine bone marrow-derived mast cells. J. Leukoc. Biol. 69: 253-262.
45. Leal-Berumen, I., D. P. Snider, C. Barajas-Lopez, and J. S. Marshall. 1996. Cholera toxin increases IL-6 synthesis and decreases TNF-α production by rat peritoneal mast cells. J. Immunol. 156: 316-321.
46. Kulka, M., L. Alexopoulou, R. A. Flavell, and D. D. Metcalfe. 2004. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol. 114: 174-182.
47. Getahun, A., and B. Heyman. 2006. How antibodies act as natural adjuvants. Immunol. Lett. 104: 38-45.
48. Heyman, B. 2003. Feedback regulation by IgG antibodies. Immunol. Lett. 88: 157-161.